FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Search
Jardiance®
Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Moving towards a rabies-free Southeast Asia
Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
Future of Diabetes
This video highlights the evolution of type 2 diabetes management
Gallimune® / Gallivac® / Volvac®
For vaccination of healthy chickens against diseases caused by the included antigens.
Hypertension
Click here for more information on Hypertension
About cardio-renal-metabolic conditions
This page provides an overview of cardiovascular, renal, and metabolic conditions
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Imagine: Ecological stoves safeguard family health in Mexico
With Fondo Para la Paz, we’ve developed ecological stoves for safer indoor cooking, enhancing respiratory health for rural Mexican families
International Women’s Day: gender and health equity
On International Women’s Day, we join forces to collectively strive for gender and health equity, empowering women in and beyond our company.
PRRS vaccine discovery for swine
PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
Zactran®
Depending on species indication (and country of registration), the product is for the treatment and metaphylaxis control of respiratory disease in cattle caused by key bacteria (Mannheimia, Pasteurella, Histophilus and Mycoplasma) and footrot disease
Living with type 2 diabetes
People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.
InSensitive Content: the impact on dermatologists
Learn about the importance of the dermatology community sharing content related to generalized pustular psoriasis on social media.
BULTAVO 3
Indicated for bluetongue disease serotype 3 in sheep and cattle
Stroke Prevention in AF
Stroke Prevention in AF
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
LastMile increases access to veterinary care in Africa
Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Striverdi® Respimat®
Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
Patient centricity and site centricity in clinical trials
We are partnering with patients, caregivers and trial site staff to design and conduct our clinical trials, to provide a better experience for all.
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype